Eli Lilly will acquire a Wisconsin-based injectable manufacturing facility from Nexus Pharmaceuticals, a drugmaker in Illinois.
The site in Pleasant Prairie, Wis., will expand Eli Lilly's global injectable portfolio, the company said April 22. The facility is expected to begin production in late 2025.